Welcome to DU! The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards. Join the community: Create a free account Support DU (and get rid of ads!): Become a Star Member Latest Breaking News General Discussion The DU Lounge All Forums Issue Forums Culture Forums Alliance Forums Region Forums Support Forums Help & Search

TeslaNova

(273 posts)
Fri Aug 20, 2021, 08:59 PM Aug 2021

Vaccine experts: Shouldn't a third vaccine be adjusted to protect against newer variants?

It seems a little odd to me that they are going to use the original vaccine when there are newer variants of the virus out there. Does this have something to do with the fact that these are mRNA type of vaccines? Anyone have any insight to this?

3 replies = new reply since forum marked as read
Highlight: NoneDon't highlight anything 5 newestHighlight 5 most recent replies
Vaccine experts: Shouldn't a third vaccine be adjusted to protect against newer variants? (Original Post) TeslaNova Aug 2021 OP
Which experts? BannonsLiver Aug 2021 #1
With a higher concentration of antibodies from an original dose booster... roamer65 Aug 2021 #2
Effectiveness research is ongoing. lapucelle Aug 2021 #3

roamer65

(36,745 posts)
2. With a higher concentration of antibodies from an original dose booster...
Fri Aug 20, 2021, 09:01 PM
Aug 2021

one can fight off Delta very well.

A reformulation requires clinical trials, etc, etc.

lapucelle

(18,252 posts)
3. Effectiveness research is ongoing.
Fri Aug 20, 2021, 09:15 PM
Aug 2021
https://www.cdc.gov/vaccines/covid-19/effectiveness-research/protocols.html

-------------------------------------------------------------------------------------------------------------------------

How to redesign COVID vaccines so they protect against variants
Lineages that can evade immunity are spurring vaccine makers to explore ways to redesign their shots.
29 January 2021

Moderna has started work on updating its mRNA vaccine to match spike mutations in 501Y.V2. The biotech company, based in Cambridge, Massachusetts, says it also intends to test the effectiveness of a third dose of its original coronavirus vaccine, and is looking into the possibility of a multivalent vaccine, said Tal Zaks, Moderna’s chief scientific officer, in a 25 January call with investors. But before deciding on any path, researchers will need to study how animals, and probably humans, respond to any potential vaccine update, says Subbarao.“It’s not going to be as simple as [altering] an amino acid site and saying ‘okay we got it’.”
Latest Discussions»General Discussion»Vaccine experts: Shouldn'...